These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35856212)

  • 61. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
    Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-effectiveness of a multidisciplinary co-management program for the older hip fracture patients in Beijing.
    Peng K; Yang M; Tian M; Chen M; Zhang J; Wu X; Ivers R; Si L
    Osteoporos Int; 2020 Aug; 31(8):1545-1553. PubMed ID: 32219498
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study.
    Yue M; Dickens BL; Yoong JS; I-Cheng Chen M; Teerawattananon Y; Cook AR
    Value Health; 2019 Dec; 22(12):1345-1354. PubMed ID: 31806190
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
    BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups.
    Michaelidis CI; Zimmerman RK; Nowalk MP; Smith KJ
    Vaccine; 2011 Apr; 29(19):3525-30. PubMed ID: 21406266
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
    Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
    Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
    Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R
    Cancer; 2017 Sep; 123(17):3253-3260. PubMed ID: 28472550
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Influenza vaccination in acute coronary syndromes patients in Thailand: the cost-effectiveness analysis of the prevention for cardiovascular events and pneumonia.
    Sribhutorn A; Phrommintikul A; Wongcharoen W; Chaikledkaew U; Eakanunkul S; Sukonthasarn A
    J Geriatr Cardiol; 2018 Jun; 15(6):413-421. PubMed ID: 30108613
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness analysis of universal influenza vaccination: Application of the susceptible-infectious-complication-recovery model.
    Yang KC; Hung HF; Chen MK; Chen SL; Fann JC; Chiu SY; Yen AM; Huang KC; Chen HH; Wang ST
    Int J Infect Dis; 2018 Aug; 73():102-108. PubMed ID: 29906602
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-utility analysis of offering a novel remunerated community pharmacist consultation service on influenza vaccination for seniors in Ontario, Canada.
    Pullagura GR; Waite NM; Houle SKD; Violette R; Wong WWL
    J Am Pharm Assoc (2003); 2019; 59(4):489-497.e1. PubMed ID: 30979576
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory analysis of the vaccine efficacy required.
    Newall AT; Dehollain JP
    Vaccine; 2014 Mar; 32(12):1323-5. PubMed ID: 24486359
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Cost-effectiveness of potential government fully-funded influenza vaccination in population with diabetes in China].
    Yang J; Yan H; Feng LZ; Yu HJ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):1000-1006. PubMed ID: 31607045
    [No Abstract]   [Full Text] [Related]  

  • 75. [Economic evaluation and prediction of hepatitis B immunization strategy in Shenzhen, China].
    Sun PP; Zhang SX; Xia Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):743-747. PubMed ID: 29996303
    [No Abstract]   [Full Text] [Related]  

  • 76. Cost-effectiveness of live-attenuated influenza vaccination among school-age children.
    Wenzel NS; Atkins KE; van Leeuwen E; Halloran ME; Baguelin M
    Vaccine; 2021 Jan; 39(2):447-456. PubMed ID: 33280855
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.
    Sisk JE; Moskowitz AJ; Whang W; Lin JD; Fedson DS; McBean AM; Plouffe JF; Cetron MS; Butler JC
    JAMA; 1997 Oct 22-29; 278(16):1333-9. PubMed ID: 9343464
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
    Allsup S; Gosney M; Haycox A; Regan M
    Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
    Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.